Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a worm enzyme soothe diabetic nerve damage?

NCT ID NCT07475065

Symptom relief Sponsor: Universitas Sebelas Maret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether an oral supplement called DLBS1033 (made from earthworm proteins) can reduce nerve damage symptoms in adults with diabetic polyneuropathy. Thirty-four people with type 2 diabetes will receive either the supplement or a placebo for 28 days, alongside standard care. Researchers will measure changes in neuropathy severity, inflammation, and nerve growth factors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DLBS1033 (lumbrokinase)
What this could lead to
If it works, this could point toward a new add-on treatment to ease nerve pain and improve nerve health in people with diabetic polyneuropathy.
What could go wrong
This is a small, early-phase trial with only 34 participants and a short 28-day treatment period. Results may not apply to everyone, and the supplement may not prove effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 40-60 years diagnosed with diabetic polyneuropathy by a neurologist or neurology resident. * Patients with HbA1c levels between 7-10% within the past 30 days. * Willing to participate and able to sign the informed consent form. Exclusion Criteria: * Pregnant, breastfeeding, or planning pregnancy. * History of other neurological diseases such as stroke, myelopathy, alcoholic neuropathy, or compressive radiculopathy. * Significant renal impairment (creatinine \> 1.5× upper limit of normal), hepatic impairment (SGOT or SGPT \> 3× upper limit of normal), or severe cardiac disease (NYHA class III-IV heart failure). * History of alcohol consumption for ≥ 5 consecutive years. * Heavy smoker (Brinkman Index \> 600). * Known allergy or intolerance to DLBS1033. * Autoimmune disease, malignancy, or acute and/or chronic inflammatory conditions other than diabetic polyneuropathy. * Participation in another interventional pharmacological clinical study within 30 days prior to screening. * Currently taking anti-inflammatory and/or antioxidant medications.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus diabetic neuropathy diabetic polyneuropathy hereditary sensory and autonomic neuropathy peripheral nervous system disorder peripheral neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus Diabetic polyneuropathy Peripheral nervous system diseases Peripheral neuropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dr. Moewardi Regional General Hospital

    Surakarta, Central Java, 57143, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.